NCT05388487 - Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

November 30, 2025

Conditions

Solid Tumor, Adult

Interventions

DRUG

HF1K16 /Arm 45 mg/m²

HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

DRUG

HF1K16 /Arm 90 mg/m²

HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

DRUG

HF1K16 /Arm 120 mg/m²

HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

DRUG

HF1K16 /Arm 160 mg/m²

HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

DRUG

HF1K16 /Arm 120 mg or 180 mg

HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes

Trial Locations (7)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Huashan Hospital Affiliated to Fudan University, Shanghai

RECRUITING

First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

Zhejiang Xiaoshan Hospital, Hangzhou

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou